| Name | GS-6201 |
| Description | GS-6201 (CVT-6883) is a selective antagonist of the adenosine A2B receptor, demonstrating high affinity and selectivity with a Ki of 22 nM for human adenosine A2B receptors. |
| In vivo | GS-6201 (2 mg/kg; p.o.) treatment displays the Cmax, dAUC and t1/2 are 1110 ng/mL, 6500 ng h/mL, and 4.25 hours, respectively [1]. GS-6201 (4 mg/kg; i.p.; every 12 h for 14 days) obviously decreases IL-6, TNF-α, E-selectin, ICAM-1, and VCAM plasma levels. GS-6201 (4 mg/kg; i.p.; every 12 h for 14 days) causes an obvious attenuation of left and right ventricular enlargement and dysfunction at 7 days, which was maintained at 14 days and also at 28 days [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 30 mg/ml (67.2 mM), Sonication and heating to 60℃ are recommended.
|
| Keywords | GS-6201 | GS 6201 | GS6201 | Inhibitor | remodeling | cardiac | caspase-1 | reactivity | airway | affinity | infarction | P1 receptor | inhibit | CVT6883 | acute | CVT 6883 | Adenosine Receptor | selectivity | myocardial |
| Inhibitors Related | Theophylline monohydrate | Diphylline | Acefylline | Nitrobenzylthioinosine | Aminophylline | Inosine | Theobromine | Istradefylline | Theophylline | Adenosine antagonist-1 | Doxofylline | FK-453 |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Neurotransmitter Receptor Compound Library | Pyroptosis Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library |
United States
